Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hoffmann

Showing results (181-190 of 312) with videos related to

Pageof 32
Sort By:
The Lancet. Infectious Diseases|November 3, 2022
The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineagesPrerna Arora, Lu Zhang, Inga Nehlmeier, et al.
The Journal of Infectious Diseases|October 12, 2011
Comparative analysis of Ebola virus glycoprotein interactions with human and bat cellsAnnika Kühl, Markus Hoffmann, Marcel A Müller, et al.
The Lancet. Infectious Diseases|November 15, 2025
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2Lu Zhang, Nianzhen Chen, Amy Eichmann, et al.
Journal of Virology|January 12, 2022
Rapid SARS-CoV-2 Adaptation to Available Cellular ProteasesM Zeeshan Chaudhry, Kathrin Eschke, Markus Hoffmann, et al.
Cellular & Molecular Immunology|May 8, 2023
Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineageInga Nehlmeier, Amy Kempf, Prerna Arora, et al.
Chemical Science|October 27, 2021
Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular propertiesTim Hempel, Katarina Elez, Nadine Krüger, et al.
Journal of Virology|October 29, 2024
Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cellsMarkus Hoffmann, Hannah Kleine-Weber, Luise Graichen, et al.
Cellular & Molecular Immunology|March 3, 2023
Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5Markus Hoffmann, Prerna Arora, Inga Nehlmeier, et al.
The Lancet. Infectious Diseases|September 16, 2023
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3Lu Zhang, Amy Kempf, Inga Nehlmeier, et al.
Emerging Microbes & Infections|July 1, 2025
Neutralizing activity against bovine H5N1 HPAIV (clade 2.3.4.4b) in human plasma after seasonal influenza vaccinationLu Zhang, Georg M N Behrens, Amy Kempf, et al.
Pageof 32

Showing results (181-190 of 312) with videos related to

Sort By:
Pageof 32
The Lancet. Infectious Diseases|November 3, 2022
The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineagesPrerna Arora, Lu Zhang, Inga Nehlmeier, et al.
The Journal of Infectious Diseases|October 12, 2011
Comparative analysis of Ebola virus glycoprotein interactions with human and bat cellsAnnika Kühl, Markus Hoffmann, Marcel A Müller, et al.
The Lancet. Infectious Diseases|November 15, 2025
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2Lu Zhang, Nianzhen Chen, Amy Eichmann, et al.
Journal of Virology|January 12, 2022
Rapid SARS-CoV-2 Adaptation to Available Cellular ProteasesM Zeeshan Chaudhry, Kathrin Eschke, Markus Hoffmann, et al.
Cellular & Molecular Immunology|May 8, 2023
Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineageInga Nehlmeier, Amy Kempf, Prerna Arora, et al.
Chemical Science|October 27, 2021
Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular propertiesTim Hempel, Katarina Elez, Nadine Krüger, et al.
Journal of Virology|October 29, 2024
Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cellsMarkus Hoffmann, Hannah Kleine-Weber, Luise Graichen, et al.
Cellular & Molecular Immunology|March 3, 2023
Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5Markus Hoffmann, Prerna Arora, Inga Nehlmeier, et al.
The Lancet. Infectious Diseases|September 16, 2023
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3Lu Zhang, Amy Kempf, Inga Nehlmeier, et al.
Emerging Microbes & Infections|July 1, 2025
Neutralizing activity against bovine H5N1 HPAIV (clade 2.3.4.4b) in human plasma after seasonal influenza vaccinationLu Zhang, Georg M N Behrens, Amy Kempf, et al.
Pageof 32